EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor

Maiko Nomoto, Tomoko Hasunuma, Cuiyuan Cai, Ippei Suzuki, Ayano Mikubo, Setsuo Funasaka, Yohei Otake, Kenya Nakai, Sanae Yasuda

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.6104 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Maiko Nomoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Food-Drug Interactions, Cytochrome P-450 CYP3A Inducers, Rabeprazole. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eisai Co., Ltd, Eisai Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted this three‐part study in healthy subjects to investigate the pharmacokinetics of tasurgratinib (orally available selective inhibitor of fibroblast growth factor receptor 1‐3) and M2 (its major metabolite) under different conditions. In Part A, subjects received tasurgratinib 35 mg either fed with a high‐fat meal or fasted. In Parts B and C, subjects received tasurgratinib 35 mg alone or with either rabeprazole (acid‐reducing agent) 20 mg (Part B) or rifampin (strong CYP3A inducer) 600 mg (Part C). Primary endpoints were maximum concentration (C max ), and areas under the plasma concentration‐time curve to time of last quantifiable concentration (AUC (0‐t) ) and extrapolated to infinite time (AUC (0‐inf) ). Forty‐two subjects were enrolled, 14 each into Parts A, B, and C. In Part A, administration of tasurgratinib with a high‐fat meal resulted in 33% reduction in C max and ∼23% reduction in AUC (0‐t) and AUC (0‐inf) of tasurgratinib, and 47% reduction in C max with ∼30% reduction in AUC (0‐t) and AUC (0‐inf) of M2. In Part B, co‐administration of rabeprazole at steady state resulted in no/weak interaction with tasurgratinib (∼8% increase in AUC (0‐t) and AUC (0‐inf) without an effect on C max ) and M2 (∼18% increase in AUC (0‐t) and AUC (0‐inf) without an effect on C max ). In Part C, co‐administration of rifampin at steady state resulted in a weak interaction with tasurgratinib (∼16% reduction in AUC (0‐t) and AUC (0‐inf) ) and M2 (∼12% reduction in AUC (0‐t) and AUC (0‐inf) ). Administration of tasurgratinib with a high‐fat meal appeared to reduce systemic exposure of tasurgratinib, however co‐administration with an acid‐reducing agent or a CYP3A inducer had a minimal impact on pharmacokinetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food-Drug InteractionsCytochrome P-450 CYP3A InducersRabeprazoleHumansMaleAdultFemaleMiddle AgedYoung AdultReceptors, Fibroblast Growth FactorRifampinCytochrome P-450 CYP3AGastric AcidSulfonamidesDrug InteractionsCross-Over StudiesArea Under CurveFastingPyrroles

Stichwörter der Autor:innen

FGFRdrug‐drug interactionsfood effectpharmacokineticstasurgratinib

Substanzen

Cytochrome P-450 CYP3A InducersRabeprazoleReceptors, Fibroblast Growth FactorRifampinCytochrome P-450 CYP3ASulfonamides1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrroles

Autor:innen und Institutionen

  • Eisai Co., Ltd., Tokyo, Japan.
  • Department of Research, Clinical Trial Center, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan.
  • Eisai Inc., Nutley, NJ, USA.

Förderung

  • Eisai Co., Ltd
  • Eisai Inc.

Zitieren

APA

Nomoto, M., Hasunuma, T., Cai, C., Suzuki, I., Mikubo, A., Funasaka, S., Otake, Y., Nakai, K., & Yasuda, S. (2024). Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6104

Vancouver

Nomoto M, Hasunuma T, Cai C, Suzuki I, Mikubo A, Funasaka S, et al. Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.6104

BibTeX
@article{Nomoto2024,
  author = {Nomoto, Maiko and Hasunuma, Tomoko and Cai, Cuiyuan and Suzuki, Ippei and Mikubo, Ayano and Funasaka, Setsuo and Otake, Yohei and Nakai, Kenya and Yasuda, Sanae},
  title = {Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.6104}
}
Kostenlos starten →